Investor Home

Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tisle...more >

Stock Quotemore >
BGNE (American Depositary Shares)

$137.78

 1.07 (0.77%)

02/22/19  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference - February 22, 2019
CAMBRIDGE, Mass. and BEIJING, China, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a co... Read More
BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma - February 19, 2019
CAMBRIDGE, Mass. and BEIJING, China, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a co... Read More

Upcoming Events

27 Feb 2019 6:00 p.m. ET28 Feb 2019 2:30 p.m. HKT

E-mail Alerts

Sign up to receive e-mail alerts